Novo Nordisk replies to BMJ investigation on incretins and pancreatic damage

BMJ (Online)

Volumn 347, Issue 7916, 2013, Pages

  Moses, Alan ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; EXENDIN 4; LIRAGLUTIDE; SITAGLIPTIN;

ACCESS TO INFORMATION; CANCER RISK; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; DRUG INDUSTRY; DRUG INFORMATION; DRUG LABELING; DRUG SAFETY; HUMAN; INFORMATION DISSEMINATION; LETTER; METHODOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS CANCER; PANCREATITIS; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RISK ASSESSMENT; WORKSHOP;

ACUTE DISEASE; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; PANCREAS; PANCREATITIS;

EID: 84880125577     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f4386     Document Type: Letter

References (9)

1. Godlee F. Secrecy does not serve us well. BMJ 2013;346:f3819. (12 June.)
2. Nyborg NCB, Mølck A-M, Madsen LW, Knudsen LB. The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species. Diabetes 2012;61:1243-9.
3. Jensen TM, Saha K, Steinberg W. Assessment of acute pancreatitis in liraglutide type 2 diabetes trials. Abstracts of papers submitted to the Joint 43rd Meeting of the American Pancreatic Association and the 17th Meeting of the International Association of Pancreatology, October 31-November 3, 2012, Miami, Florida. Pancreas 2012:41:1370-1
4. Novo Nordisk, post marketing data on file. June 2013.
5. Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide - the FDA's review of a new antidiabetic therapy. N Engl J Med 2010;362:774-7.
6. Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 200932:834-8.
7. Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-604.
8. Kahn SE. Incretin therapy and islet pathology: a time for caution. Diabetes 2013;62:2178-80.
9. Nauck MA. A critical analysis of the clinical use of incretin-based therapies: the benefits by far outweigh the potential risks. Diabetes Care 2013;36:2126-32.